Clinical Trial Update: A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone [Phase 3]

View source ↗

Summary

A Phase 3 imaging study evaluating D2 receptor occupancy and fMRI brain responses in schizophrenia patients treated with lurasidone has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• lurasidone (lurasidone)

Snippet

Sponsor: University of California, Irvine | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED